Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 184,114 shares, a growth of 56.8% from the August 31st total of 117,438 shares. Based on an average trading volume of 4,206 shares, the short-interest ratio is presently 43.8 days. Approximately 0.2% of the shares of the stock are short sold.
Oxford BioMedica Stock Performance
Shares of OTCMKTS OXBDF remained flat at $6.65 during mid-day trading on Wednesday. 16,707 shares of the stock traded hands, compared to its average volume of 1,634. Oxford BioMedica has a 12 month low of $5.80 and a 12 month high of $12.61. The firm’s fifty day moving average price is $7.03 and its two-hundred day moving average price is $7.71.
Analyst Ratings Changes
Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Oxford BioMedica currently has a consensus rating of “Hold”.
Oxford BioMedica Company Profile
Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.
Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services.
See Also
- Five stocks we like better than Oxford BioMedica
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
- 3 Emerging Biotech Stocks With Significant Upside Potential
- Treasury Yields Haven’t Been This High Since 2007—3 ETFs to Watch
- 3 Healthcare Dividend Stocks Offering More Than Just Income
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
